[
    {
        "pregunta": "1. What are the first-line therapies recommended for gout flares according to the 2020 American College of Rheumatology Guideline?",
        "respuesta": "The first-line therapies recommended for gout flares according to the 2020 American College of Rheumatology Guideline are oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate. The choice among these options should be based on patient factors and preferences.",
        "contexto": [
            "<p>|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH (the choice of colchicine, NSAIDs, or glucocorticoids should be made based on patient factors and preferences).|32|High†|",
            "recommended for patients experiencing a gout flare for whom the above antiinflammatory therapies are either ineffective, poorly tolerated, or contraindicated. Treatment with glucocorticoids (intramuscular, intravenous, or intraarticular) over IL-1 inhibitors or ACTH is strongly recommended for patients who are unable to take oral medications. The Voting Panel's recommendation of colchicine, NSAIDs, or glucocorticoids as preferred first-line therapies was based on substantial trial data",
            "obese, regardless of disease activity. Certainty of evidence For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH (the choice of colchicine, NSAIDs, or glucocorticoids should be made based on patient factors and preferences). When colchicine is the chosen agent, we strongly recommend low-dose colchicine over high-dose",
            "is not absolute and not meant to be pursued at \"any cost.\" Even strong recommendations require sound clinical judgment to balance the potential clinical benefits and harms (including costs) of medical decisions Gout flare management Using colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate firstline therapy for gout flares over IL-1 inhibitors or adrenocorticotropic hormone (ACTH) is strongly recommended for patients experiencing a gout flare. Given",
            "|When the decision is made that ULT is indicated while the patient is experiencing a gout flare, we conditionally recommend starting ULT during the gout flare over starting ULT after the gout flare has resolved.|6|Moderate|\n|We strongly recommend against pegloticase as first-line therapy.|10|Moderate†|</p>"
        ]
    },
    {
        "pregunta": "2. How is the choice between colchicine, NSAIDs, and glucocorticoids determined in the management of gout flares?",
        "respuesta": "The choice between colchicine, NSAIDs, and glucocorticoids in the management of gout flares should be determined based on patient factors and preferences. According to the 2020 American College of Rheumatology Guideline, oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) are recommended as first-line therapy for gout flares. Patients and healthcare providers should consider factors such as effectiveness, tolerability, contraindications, and patient preferences when selecting the most appropriate medication for managing gout flares.",
        "contexto": [
            "<p>|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH (the choice of colchicine, NSAIDs, or glucocorticoids should be made based on patient factors and preferences).|32|High†|",
            "obese, regardless of disease activity. Certainty of evidence For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH (the choice of colchicine, NSAIDs, or glucocorticoids should be made based on patient factors and preferences). When colchicine is the chosen agent, we strongly recommend low-dose colchicine over high-dose",
            "is not absolute and not meant to be pursued at \"any cost.\" Even strong recommendations require sound clinical judgment to balance the potential clinical benefits and harms (including costs) of medical decisions Gout flare management Using colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate firstline therapy for gout flares over IL-1 inhibitors or adrenocorticotropic hormone (ACTH) is strongly recommended for patients experiencing a gout flare. Given",
            "recommended for patients experiencing a gout flare for whom the above antiinflammatory therapies are either ineffective, poorly tolerated, or contraindicated. Treatment with glucocorticoids (intramuscular, intravenous, or intraarticular) over IL-1 inhibitors or ACTH is strongly recommended for patients who are unable to take oral medications. The Voting Panel's recommendation of colchicine, NSAIDs, or glucocorticoids as preferred first-line therapies was based on substantial trial data",
            "the chosen agent, we strongly recommend low-dose colchicine over high-dose colchicine given its similar efficacy and fewer adverse effects. High † For patients experiencing a gout flare for whom other antiinflammatory therapies are poorly tolerated or contraindicated, we conditionally recommend using IL-1 inhibition over no therapy (beyond supportive/ analgesic treatment). Moderate For patients who may receive NPO, we strongly recommend glucocorticoids (intramuscular, intravenous, or"
        ]
    },
    {
        "pregunta": "3. What is the recommendation for using IL-1 inhibitors in patients with gout flares who cannot tolerate other anti-inflammatory therapies?",
        "respuesta": "The recommendation for using IL-1 inhibitors in patients with gout flares who cannot tolerate other anti-inflammatory therapies is that it is conditionally recommended over no therapy (beyond supportive/analgesic treatment). This recommendation is based on moderate certainty of evidence according to the retrieved documents.",
        "contexto": [
            "recommended for patients experiencing a gout flare for whom the above antiinflammatory therapies are either ineffective, poorly tolerated, or contraindicated. Treatment with glucocorticoids (intramuscular, intravenous, or intraarticular) over IL-1 inhibitors or ACTH is strongly recommended for patients who are unable to take oral medications. The Voting Panel's recommendation of colchicine, NSAIDs, or glucocorticoids as preferred first-line therapies was based on substantial trial data",
            "<p>|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH (the choice of colchicine, NSAIDs, or glucocorticoids should be made based on patient factors and preferences).|32|High†|",
            "|When colchicine is the chosen agent, we strongly recommend low-dose colchicine over high-dose colchicine given its similar efficacy and fewer adverse effects.| | |\n|For patients experiencing a gout flare for whom other antiinflammatory therapies are poorly tolerated or contraindicated, we conditionally recommend using IL-1 inhibition over no therapy (beyond supportive/analgesic treatment).|33|Moderate|",
            "the chosen agent, we strongly recommend low-dose colchicine over high-dose colchicine given its similar efficacy and fewer adverse effects. High † For patients experiencing a gout flare for whom other antiinflammatory therapies are poorly tolerated or contraindicated, we conditionally recommend using IL-1 inhibition over no therapy (beyond supportive/ analgesic treatment). Moderate For patients who may receive NPO, we strongly recommend glucocorticoids (intramuscular, intravenous, or",
            "of potential benefits outweighs the harms and costs of the drug. ‡ For patients with minimal disease activity, the smaller potential benefits do not outweigh the harms and costs of the drug. Using topical ice as an adjuvant treatment over no adjuvant treatment is conditionally recommended for patients experiencing a gout flare. Using an IL-1 inhibitor over no therapy (beyond supportive/analgesic treatment) is conditionally recommended for patients experiencing a gout flare for whom the above"
        ]
    },
    {
        "pregunta": "4. What is the preferred adjuvant treatment for gout flares, according to the guideline?",
        "respuesta": "The preferred adjuvant treatment for gout flares, according to the retrieved documents, is using topical ice as an adjuvant treatment over no adjuvant treatment. This recommendation is based on the guideline's suggestion for patients experiencing a gout flare.",
        "contexto": [
            "<p>|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH (the choice of colchicine, NSAIDs, or glucocorticoids should be made based on patient factors and preferences).|32|High†|",
            "recommended for patients experiencing a gout flare for whom the above antiinflammatory therapies are either ineffective, poorly tolerated, or contraindicated. Treatment with glucocorticoids (intramuscular, intravenous, or intraarticular) over IL-1 inhibitors or ACTH is strongly recommended for patients who are unable to take oral medications. The Voting Panel's recommendation of colchicine, NSAIDs, or glucocorticoids as preferred first-line therapies was based on substantial trial data",
            "of potential benefits outweighs the harms and costs of the drug. ‡ For patients with minimal disease activity, the smaller potential benefits do not outweigh the harms and costs of the drug. Using topical ice as an adjuvant treatment over no adjuvant treatment is conditionally recommended for patients experiencing a gout flare. Using an IL-1 inhibitor over no therapy (beyond supportive/analgesic treatment) is conditionally recommended for patients experiencing a gout flare for whom the above",
            "obese, regardless of disease activity. Certainty of evidence For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH (the choice of colchicine, NSAIDs, or glucocorticoids should be made based on patient factors and preferences). When colchicine is the chosen agent, we strongly recommend low-dose colchicine over high-dose",
            "is not absolute and not meant to be pursued at \"any cost.\" Even strong recommendations require sound clinical judgment to balance the potential clinical benefits and harms (including costs) of medical decisions Gout flare management Using colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate firstline therapy for gout flares over IL-1 inhibitors or adrenocorticotropic hormone (ACTH) is strongly recommended for patients experiencing a gout flare. Given"
        ]
    },
    {
        "pregunta": "5. What lifestyle factors are conditionally recommended to be limited in patients with gout?",
        "respuesta": "The lifestyle factors that are conditionally recommended to be limited in patients with gout, regardless of disease activity, according to the retrieved documents are:\n\n- Limiting alcohol intake\n- Limiting purine intake\n- Limiting high-fructose corn syrup intake\n- Weight loss for overweight/obese patients with gout\n\nAdditionally, it is conditionally recommended against adding vitamin C supplementation for patients with gout.\n\nThis information is based on the guidelines provided in the retrieved documents.",
        "contexto": [
            "<p>|Recommendation|PICO|Certainty of evidence|\n|---|---|---|\n|For patients with gout, regardless of disease activity, we conditionally recommend limiting alcohol intake.|41|Low|\n|For patients with gout, regardless of disease activity, we conditionally recommend limiting purine intake.|42|Low|\n|For patients with gout, regardless of disease activity, we conditionally recommend limiting high-fructose corn syrup.|43|Very low|",
            "for patients with gout, regardless of disease activity. Limiting purine intake is conditionally recommended for patients with gout, regardless of disease activity. Limiting high-fructose corn syrup intake is conditionally recommended for patients with gout, regardless of disease activity. Using a weight loss program (no specific program endorsed) is conditionally recommended for those patients with gout who are overweight/ obese, regardless of disease activity. Certainty of evidence For",
            "in these guidelines are supported by higher quality studies than the 2012 ACR Guidelines for the Management of Gout. This resulted in a more focused, less proscriptive document. Where certainty of data is less than moderate or high, conditional recommendations made herein are meant to highlight those decisions that would benefit from a shared patient-provider decision-making process. This would include areas such as diet, lifestyle, or concomitant medications that might affect SU levels, and",
            "|For overweight/obese patients with gout, regardless of disease activity, we conditionally recommend weight loss.|46|Very low|\n|For patients with gout, regardless of disease activity, we conditionally recommend against adding vitamin C supplementation.|48|Low|</p>",
            "lifestyle, or concomitant medications that might affect SU levels, and for which the Patient Panel requested guidance. The Voting Panel aimed to provide guidance without implying any \"patient-blaming\" for the manifestations of gout given its strong genetic determinants. Indications for ULT are expanded from the 2012 ACR Guidelines for the Management of Gout, but consistent with the 2016 update of the EULAR gout recommendations This updated guideline effort also identifies several areas that"
        ]
    },
    {
        "pregunta": "6. What is the recommendation regarding the use of vitamin C supplementation in patients with gout?",
        "respuesta": "The recommendation regarding the use of vitamin C supplementation in patients with gout is that it is conditionally recommended against adding vitamin C supplementation. This recommendation is based on the guidelines provided in the retrieved documents.",
        "contexto": [
            "|For overweight/obese patients with gout, regardless of disease activity, we conditionally recommend weight loss.|46|Very low|\n|For patients with gout, regardless of disease activity, we conditionally recommend against adding vitamin C supplementation.|48|Low|</p>",
            "<p>|Recommendation|PICO|Certainty of evidence|\n|---|---|---|\n|For patients with gout, regardless of disease activity, we conditionally recommend limiting alcohol intake.|41|Low|\n|For patients with gout, regardless of disease activity, we conditionally recommend limiting purine intake.|42|Low|\n|For patients with gout, regardless of disease activity, we conditionally recommend limiting high-fructose corn syrup.|43|Very low|",
            "<p>|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH (the choice of colchicine, NSAIDs, or glucocorticoids should be made based on patient factors and preferences).|32|High†|",
            "<p>|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients with gout taking their first XOI monotherapy at maximum-tolerated or FDA-indicated dose who are not at SU target and/or have continued frequent gout flares or nonresolving subcutaneous tophi, we conditionally recommend switching the first XOI to an alternate XOI agent over adding a uricosuric agent.|24|Very low|",
            "<p><strong>Table 2. Recommendations for choice of initial urate-lowering therapy (ULT) in patients with gout*</strong>\n|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients starting any ULT, we strongly recommend allopurinol over all other ULT as the preferred first-line agent for all patients, including in those with CKD stage &gt;3.|10|Moderate|\n|We strongly recommend a xanthine oxidase inhibitor over probenecid for those with CKD stage &gt;3.| | |"
        ]
    },
    {
        "pregunta": "7. When should hydrochlorothiazide be switched to an alternate antihypertensive in patients with gout?",
        "respuesta": "Based on the retrieved documents, it is recommended to switch hydrochlorothiazide to an alternate antihypertensive in patients with gout, regardless of disease activity, when feasible. This recommendation is based on very low certainty of evidence.",
        "contexto": [
            "<p>|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients with gout, regardless of disease activity, we conditionally recommend switching hydrochlorothiazide to an alternate antihypertensive when feasible.|47|Very low|\n|We conditionally recommend choosing losartan preferentially as an antihypertensive when feasible.|47|Very low|",
            "weight increases SU concentration by 1-2 mg/dl within 2 hours of ingestion Weight loss. The Voting Panel considered the impact of weight loss and specific dietary programs (including the DASH diet Management of concurrent medications Switching hydrochlorothiazide to an alternate antihypertensive when feasible is conditionally recommended for patients with gout, regardless of disease activity. Choosing losartan preferentially as an antihypertensive agent when feasible is conditionally",
            "preferentially as an antihypertensive agent when feasible is conditionally recommended for patients with gout, regardless of disease activity. Stopping low-dose aspirin (for patients taking this medication for appropriate indications) is conditionally recommended against for patients with gout, regardless of disease activity. Adding or switching cholesterol-lowering agents to fenofibrate is conditionally recommended against for patients with gout, regardless of disease activity. Medications",
            "<p>|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients with gout taking their first XOI monotherapy at maximum-tolerated or FDA-indicated dose who are not at SU target and/or have continued frequent gout flares or nonresolving subcutaneous tophi, we conditionally recommend switching the first XOI to an alternate XOI agent over adding a uricosuric agent.|24|Very low|",
            "in incident gout flares over 3 years. However, the development of incident gout was low for both ULT and placebo arms (<1% versus 5%) Recommendations for choice of initial ULT for patients with gout Treatment with allopurinol as the preferred first-line agent, over all other ULTs, is strongly recommended for all patients, including those with moderate-to-severe CKD (stage ≥3). The Voting Panel strongly recommended allopurinol as the preferred first-line agent given its efficacy when dosed"
        ]
    },
    {
        "pregunta": "8. What is the recommended antihypertensive agent of choice for patients with gout?",
        "respuesta": "The recommended antihypertensive agent of choice for patients with gout, based on the retrieved documents, is losartan. Losartan is conditionally recommended as the preferred antihypertensive agent when feasible for patients with gout, regardless of disease activity.",
        "contexto": [
            "<p>|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients with gout, regardless of disease activity, we conditionally recommend switching hydrochlorothiazide to an alternate antihypertensive when feasible.|47|Very low|\n|We conditionally recommend choosing losartan preferentially as an antihypertensive when feasible.|47|Very low|",
            "preferentially as an antihypertensive agent when feasible is conditionally recommended for patients with gout, regardless of disease activity. Stopping low-dose aspirin (for patients taking this medication for appropriate indications) is conditionally recommended against for patients with gout, regardless of disease activity. Adding or switching cholesterol-lowering agents to fenofibrate is conditionally recommended against for patients with gout, regardless of disease activity. Medications",
            "<p><strong>Table 2. Recommendations for choice of initial urate-lowering therapy (ULT) in patients with gout*</strong>\n|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients starting any ULT, we strongly recommend allopurinol over all other ULT as the preferred first-line agent for all patients, including in those with CKD stage &gt;3.|10|Moderate|\n|We strongly recommend a xanthine oxidase inhibitor over probenecid for those with CKD stage &gt;3.| | |",
            "<p>|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH (the choice of colchicine, NSAIDs, or glucocorticoids should be made based on patient factors and preferences).|32|High†|",
            "in incident gout flares over 3 years. However, the development of incident gout was low for both ULT and placebo arms (<1% versus 5%) Recommendations for choice of initial ULT for patients with gout Treatment with allopurinol as the preferred first-line agent, over all other ULTs, is strongly recommended for all patients, including those with moderate-to-severe CKD (stage ≥3). The Voting Panel strongly recommended allopurinol as the preferred first-line agent given its efficacy when dosed"
        ]
    },
    {
        "pregunta": "9. What is the recommendation regarding low-dose aspirin in patients with gout who are taking it for appropriate indications?",
        "respuesta": "The recommendation regarding low-dose aspirin in patients with gout who are taking it for appropriate indications is that it is conditionally recommended against stopping low-dose aspirin, regardless of disease activity. This recommendation is based on the guidelines provided in the retrieved documents.",
        "contexto": [
            "preferentially as an antihypertensive agent when feasible is conditionally recommended for patients with gout, regardless of disease activity. Stopping low-dose aspirin (for patients taking this medication for appropriate indications) is conditionally recommended against for patients with gout, regardless of disease activity. Adding or switching cholesterol-lowering agents to fenofibrate is conditionally recommended against for patients with gout, regardless of disease activity. Medications",
            "for patients with gout, regardless of disease activity. Medications noted above are known to have effects on SU concentrations Recognizing that there are few practical alternatives to lowdose aspirin, the Voting Panel specifically recommended against its cessation as a means of SU reduction when a patient is taking it for an appropriate indication. Likewise, the Voting Panel specifically recommended against adding or switching cholesterollowering agents (e.g., statins, bile acid sequestrants,",
            "the chosen agent, we strongly recommend low-dose colchicine over high-dose colchicine given its similar efficacy and fewer adverse effects. High † For patients experiencing a gout flare for whom other antiinflammatory therapies are poorly tolerated or contraindicated, we conditionally recommend using IL-1 inhibition over no therapy (beyond supportive/ analgesic treatment). Moderate For patients who may receive NPO, we strongly recommend glucocorticoids (intramuscular, intravenous, or",
            "<p>|Recommendation|PICO|Certainty of evidence|\n|---|---|---|\n|For patients with gout, regardless of disease activity, we conditionally recommend limiting alcohol intake.|41|Low|\n|For patients with gout, regardless of disease activity, we conditionally recommend limiting purine intake.|42|Low|\n|For patients with gout, regardless of disease activity, we conditionally recommend limiting high-fructose corn syrup.|43|Very low|",
            "|When colchicine is the chosen agent, we strongly recommend low-dose colchicine over high-dose colchicine given its similar efficacy and fewer adverse effects.| | |\n|For patients experiencing a gout flare for whom other antiinflammatory therapies are poorly tolerated or contraindicated, we conditionally recommend using IL-1 inhibition over no therapy (beyond supportive/analgesic treatment).|33|Moderate|"
        ]
    },
    {
        "pregunta": "10. What are the indications for initiating pharmacologic urate-lowering therapy (ULT) in patients with gout according to the guideline?",
        "respuesta": "The indications for initiating pharmacologic urate-lowering therapy (ULT) in patients with gout according to the guideline include:\n\n- Having ≥1 subcutaneous tophi\n- Comorbid moderate-to-severe chronic kidney disease (CKD) stage ≥3\n- Serum urate (SU) concentration >9 mg/dl\n- Urolithiasis\n\nIt is conditionally recommended against initiating ULT in patients with gout experiencing their first gout flare unless they have specific comorbidities as mentioned above.",
        "contexto": [
            "<h1>Table 1. Indications for pharmacologic urate-lowering therapy (ULT)*</h1>",
            "<p><strong>Table 2. Recommendations for choice of initial urate-lowering therapy (ULT) in patients with gout*</strong>\n|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients starting any ULT, we strongly recommend allopurinol over all other ULT as the preferred first-line agent for all patients, including in those with CKD stage &gt;3.|10|Moderate|\n|We strongly recommend a xanthine oxidase inhibitor over probenecid for those with CKD stage &gt;3.| | |",
            "course of guideline development, it remains Food and Drug Administration (FDA) approved, and we therefore considered the data in relation to relevant PICO questions. To facilitate the 2 NMAs, we also considered medications not available in the US to permit comparisons with other available medications in the network analysis. | 747 RESULTS/RECOMMENDATIONS Indications for pharmacologic ULT Initiating ULT is strongly recommended for gout patients with any of the following: ≥1 subcutaneous tophi;",
            "specific to these subgroups. Initiating ULT is conditionally recommended against in patients with gout experiencing their first gout flare. However, initiating ULT is conditionally recommended for patients with comorbid moderateto-severe CKD (stage ≥3), SU concentration >9 mg/ dl, or urolithiasis. While conditionally recommending against ULT initiation following the first gout flare in a patient with \"uncomplicated\" gout, the Voting Panel considered Patient Panel input and recognized that there",
            "lifestyle, or concomitant medications that might affect SU levels, and for which the Patient Panel requested guidance. The Voting Panel aimed to provide guidance without implying any \"patient-blaming\" for the manifestations of gout given its strong genetic determinants. Indications for ULT are expanded from the 2012 ACR Guidelines for the Management of Gout, but consistent with the 2016 update of the EULAR gout recommendations This updated guideline effort also identifies several areas that"
        ]
    }
]